Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diag-nosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF
10.11904/j.issn.1002-3070.2016.06.010
- VernacularTitle:重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响
- Author:
Rui ZHANG
;
Zhiyu WANG
;
Shuai WANG
;
Hui ZHAO
- Keywords:
Non-small cell lung cancer;
Bone metastases;
Chemotherapy;
Recombinant human endosta-tin;
Vascular endothelial growth factor
- From:
Practical Oncology Journal
2016;30(6):527-532
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of recombinant human endostatin ( Rh-endostatin ) com-bined with vinorelbine -cisplatin( NP) regimen for newly diagnosed patients with advanced non -small cell lung cancer(NSCLC)with bone metastases and the impact on expression of serum vascular endothelial growth factor (VEGF).Methods From January 1,2009 to February 1,2012,a total of 40 with newly diagnosed,advanced NSCLC patients with bone metastases were enrolled in this study and randomly assigned to the treatment (N=20) or control(N=20)group.The control group was only given the NP regimen chemotherapy and the treatment group was treated with Rh-endostatin combined with NP regimen .The changes in clinical effects of the two groups and serum VEGF levels were observed .Results After two cycles of systemic chemotherapy ,objective response rate (ORR)and disease control rate(DCR)of the treatment group were 30.0% and 80.0%significantly higher than 5.0%and 45.0%of the control group(P<0.05).Serum VEGF Level did not significantly change before and af-ter treatments in the two groups (P>0.05).Conclusion Rh-endostatin combined with NP regimen can im-prove the efficiency of treatment for newly diagnosed patients with advanced NSCLC with bone metastases and does not increase adverse reactions whereas no significant difference in serum VEGF Levels .
